Also in the breast cancer cell line MDA-MB-453, treatment with the AR-agonist CI-4AS-1 resulted in a significant downregulation of miR-125b and miR-100 and induced the expression of their target gene metalloprotease-13 (MMP13) [67]. Here, AR is linked to breast carcinoma.